



IFW
CT2777A US - CIP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Nancy S. Turover
Type or print name

N. S. Turover
Signature

Feb. 17, 2006
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
PRASAD CHATURVEDULA, et al.
APPLICATION NO: **10/729155**
FILED: **12/05/2003**
FOR: **CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS**

ART UNIT: **1624**
EXAMINER: **BALASUBRAMANIAN, V.**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449 which are supplemental to those which may have been previously cited.

Pursuant to the OG Notice of August 5, 2003, for U.S. national applications filed after June 30, 2003, the requirement for submitting a copy of each cited U.S. patent and each cited U.S. patent application publication is waived, therefore, copies of the U.S. patent and U.S. patent publications are not submitted. However, applicant is willing to send copies of any or all of these references at the Examiner's request. Copies of the other cited references are enclosed herewith.

Please note that English translations of WO 2005/10043, WO 2005/10032 or WO 2005/10036 are not available. However, we provide herewith the English Abstracts which

02/22/2006 SHASSEN1 00000067 193880 10729155

01 FC:1806 180.00 DA

appear of the cover page of these references. All other foreign language documents are referenced to the corresponding English equivalent for the Examiner's convenience.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

The Commissioner is hereby authorized to charge all necessary fees as set forth in 37 CFR 1.17(p) to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company. An additional copy of this paper is enclosed.

Respectfully submitted,

Date: 2/16/2006



Shah R. Makujina
Patent Department
Attorney for Applicant
Reg. No. 41,174
Phone: 203-677-7268

Bristol-Myers Squibb Company
P.O. Box 4000
Princeton, NJ 08543-4000

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO. CT-2777A US - CIP (1)

APPLICATION NO. 10/729,155

APPLICANT Chaturvedula, et al.

FILING DATE 05 DEC 2003



(Use several sheets if necessary)

U.S. RELATED PATENT APPLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	11/247,697 [10243-NP]	11 OCT 2005	Chaturvedula, <u>et al.</u>			
	AB	11/291,670 [10466-NP]	01 DEC 2005	Chaturvedula, <u>et al.</u>			
	AC						
	AD						

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AE	2001/0036946 A1	01 NOV 2001	Rudolf, <u>et al.</u>			
	AF	2003/0191068 A1 [English equivalent of WO 03/070753]	09 OCT 2003	Trunk and Weiler			
	AG	2004/0214819 A1	28 OCT 2004	Rudolf, <u>et al.</u>			
	AH	2004/0229861 A1	18 NOV 2004	Burgey, <u>et al.</u>			
	AI	2004/0248816A1	09 DEC 2004	Doods, <u>et al.</u>			
	AJ	2005/0032783 A1	10 FEB 2005	Doods, <u>et al.</u>			
	AK	2005/0065094 A1	24 MAR 2005	Davidai			
	AL	2005/0215546 A1	29 SEP 2005	Hurnaus, <u>et al.</u>			
	AM	2005/0215576 A1 [10260-NP]	29 SEP 2005	Degnan, <u>et al.</u>			
	AN	2005/0227968 A1 [English equivalent of WO2005/084672]	05 OCT 2005	Lustenberger, <u>et al.</u>			
	AO	2005/0233980 A1 [English equivalent of WO2005/102322]	20 OCT 2005	Doods and Rudolf			
	AP	2005/0234054 A1	20 OCT 2005	Mueller, <u>et al.</u>			
	AQ	2005/0234067 [English equivalent of WO2005/092880]	20 OCT 2005	Mueller, <u>et al.</u>			
	AR	2005/0250763 A1	10 NOV 2005	Mueller, <u>et al.</u>			
	AS	2005/0256098	17 NOV 2005	Burgey, <u>et al.</u>			

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. CT-2777A US – CIP (1)

APPLICATION NO. 10/729,155

APPLICANT Chaturvedula, et al.

FILING DATE 05 DEC 2003

U.S. PATENT APPLICATION PUBLICATIONS, *continued*

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AT	US2005/0256099 [English equivalent of WO2005/103037]	17 NOV 2005	Mueller, <u>et al.</u>			
	AU	2005/0272955 A1 [English equivalent of WO2005/121078]	08 DEC 2005	Zimmer, <u>et al.</u>			
	AW						
	AX						
	AY						
	AZ						

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	APPLICANT	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	BE	WO 03/070753] [see English equivalent US 2003/191068]	28 AUG 2003	Boehringer Ingelheim Pharma			<input checked="" type="checkbox"/>	<input type="checkbox"/>
	BF	WO 2004/087649 A2	14 OCT 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
	BG	WO 2004/092168A1	28 OCT 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
	BH	WO 2004/092166A2	28 OCT 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. CT-2777A US – CIP (1)

APPLICATION NO. 10/729,155

APPLICANT Chaturvedula, *et al.*

FILING DATE 05 DEC 2003

FOREIGN PATENT DOCUMENTS, continued

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	APPLICANT	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	BI	WO 2005/000807	06 JAN 2005	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
	BJ	WO 2005/009962	03 FEB 2005	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
	BK	WO 2005/013894	17 FEB 2005	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
	BL	WO2005/065779 [10135 PCT]	21 JUL 2005	Bristol-Myers Squibb Co.			<input type="checkbox"/>	<input type="checkbox"/>
	BM	WO 2005/072308	11 AUG 2005	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
	BN	WO 2005/095383 [10260-PCT]	13 OCT 2005	Bristol-Myers Squibb Co.			<input type="checkbox"/>	<input type="checkbox"/>
	BO	WO 2005/102322 (see English equivalent US 2005/0233980]	03 NOV 2005	Boehringer Ingelheim Pharma			<input checked="" type="checkbox"/>	<input type="checkbox"/>
	BP	WO 2005/092880 [see English equivalent 2005/0234067]	06 OCT 2005	Boehringer Ingelheim Pharma			<input checked="" type="checkbox"/>	<input type="checkbox"/>
	BQ	WO 2005/100343 [English Abstract]	27 OCT 2005	Boehringer Ingelheim Pharma			<input type="checkbox"/>	<input checked="" type="checkbox"/>
	BR	WO 2005/100352 [English Abstract]	27 OCT 2005	Boehringer Ingelheim Pharma			<input type="checkbox"/>	<input checked="" type="checkbox"/>
	BS	WO/2005/100360 [English Abstract]	27 OCT 2005	Boehringer Ingelheim Pharma			<input type="checkbox"/>	<input checked="" type="checkbox"/>
	BT	WO 2005/103037 [see English equivalent US2005/0256099]	03 NOV 2005	Boehringer Ingelheim Pharma			<input checked="" type="checkbox"/>	<input type="checkbox"/>
	BU	WO 2005/121078 [see English equivalent 2005/0272955]	22 DEC 2005	Grünenthal GMBH			<input checked="" type="checkbox"/>	<input type="checkbox"/>
	BV	WO2005/084672 [see English equivalent 2005/0227968]	15 SEP 2005	Boehringer Ingelheim Pharma			<input checked="" type="checkbox"/>	<input type="checkbox"/>
	BW							

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. CT-2777A US – CIP (1)

APPLICATION NO. 10/729,155

APPLICANT Chaturvedula, et al.

FILING DATE 05 DEC 2003

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

BX	CARLSTRÖM, A.-S. and FREJD, T., "Palladium-Catalyzed Synthesis of Didehydroamino Acid Derivatives, <u>Synthesis</u> , 1989, 6, 414-418
BY	CARLSTRÖM, A.-S. and FREJD, T., "Palladium-Catalyzed Bis-coupling of Dihaloaromatics with 2-Amidoacrylates", <u>J. Org. Chem.</u> , 1991, 56, 1289-1293
BZ	DYGOS, J.H., <u>et al.</u> , "A Convenient Asymmetric Synthesis of the Unnatural Amino Acid 2,6-Dimethyl-L-tyrosine", <u>Synthesis</u> , 1992, 741-743
CA	RUDOLF, K., <u>et al.</u> , "Development of Human Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists. 1. Potent and Selective Small Molecule CGRP Antagonists. 1-[N ² -[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidiny]carbonyl]-D-tyrosyl] L-lysyl]-4-(4-pyridinyl)piperazine: The First CGRP Antagonist for Clinical Trials in Acute Migraine", <u>J. Med. Chem.</u> 2005, 48, 5921-5931
CB	XIN, Z., <u>et al.</u> , "Potent, Selective Inhibitors of Protein Tyrosine Phosphatase IB", <u>Bioorg. & Med. Chem. Lett.</u> , 2003, 13, 1887-1890
CC	
CD	
CE	
CF	
EXAMINER	
DATE CONSIDERED	

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.